Probing drug pharmacokinetics by QENS. The effect of cisplatin-like anticancer agents on HSA blood protein.
Inelastic neutron scattering will be applied to probe the interaction between cisplatin-like anticancer drugs and human serum albumin (HSA), based on their effect on the dynamical behaviour of the protein. This drug-HSA interaction is associated with drug transport/bioavailability and with antitumour efficacy. These are major limiting factors in cancer treatment, that can severely undermine chemotherapy. A dinuclear palladium compound developed by the team will be tested, in addition to the clinically used drug cisplatin. In combination with extensive QENS data gathered by the applicants on the impact of these drugs on human cancer cells and DNA, as well as with synchrotron-based THz results on drug-HSA interplay, this study is expected to contribute to a better understanding of the mode of action of metallodrugs, with a view to improve their therapeutic efficiency. This is a re-submission of proposal 88056 after revision according to reviewers comments (marked as underlined text).
The data is currently only available to download if you are a member of the proposal team.
The recommended format for citing this dataset in a research publication is in the following format:
GARCIA SAKAI Victoria; L. A. E. Batista de Carvalho; MPM Marques; OLLIVIER Jacques and SEYDEL Tilo. (2023). Probing drug pharmacokinetics by QENS. The effect of cisplatin-like anticancer agents on HSA blood protein.. Institut Laue-Langevin (ILL) doi:10.5291/ILL-DATA.8-04-957
This data is not yet public
This data is not yet public
ILL has partnered with DataCite as the registration agency
for data persistent identifiers.